Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.9
4.9
Journals
Pharmaceutics
Special Issues
Radionuclide-Based Theranostics
share announcement

Radionuclide-Based Theranostics

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Gene and Cell Therapy".

Deadline for manuscript submissions: closed (20 April 2022) | Viewed by 9189

Special Issue Editors

Dr. Mohamed Altai

E-Mail Website
Guest Editor
Division of Oncology and Pathology, Department of Clinical Sciences, Kamprad Laboratory, Lund University, 22243 Lund, Sweden
Interests: targeted radionuclide therapy; radionuclide molecular imaging; radiolabelling chemistry; scaffold proteins; antibody
Special Issues, Collections and Topics in MDPI journals
Dr. Joanna Strand

E-Mail Website
Guest Editor
Division of Oncology and Pathology, Department of Clinical Sciences, Kamprad Laboratory, Lund University, 22243 Lund, Sweden
Interests: targeted radionuclide therapy; nuclear medicine in oncology; prostate cancer

Special Issue Information

Respected Colleagues,

The theranostics paradigm consists of the possibility of labeling a molecular targeting vector (e.g., peptides or antibodies) either with diagnostic (e.g., positron or gamma-emitters) or therapeutic radionuclides (e.g., alfa, beta-emitters, or auger electron-emitters) paving the way for personalizing cancer treatment, with the possibility of using the same targeting agent for diagnostics, staging, monitoring of treatment response, and therapy. In recent years, the field of cancer theranostics has evolved considerably due to the definition of suitable biological targets and targeting strategies (e.g., SSTR- and PSMA-based concepts). The evolving development of theranostics in oncology is making the treatment of malignant diseases feasible and holds great promise for improved patient outcomes in the future.

We hereby would like to invite you to contribute to this Special Issue. Review or original research articles highlighting current progress in the development of potential targeting agents and the different aspects of theranostics will form the basis of this Special Issue on “Radionuclide-Based Theranostics”. We look forward to your contributions.

Dr. Mohamed Altai
Dr. Joanna Strand
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • theranostics
  • imaging (PET, SPECT)
  • nuclear medicine (preclinical and clinical)
  • radionuclide therapy
  • dosimetry
  • drug development

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

13 pages, 2810 KiB  
Article
Hematological Toxicity in Mice after High Activity Injections of 177Lu-PSMA-617
by Amanda Kristiansson, Oskar Vilhelmsson Timmermand, Mohamed Altai, Joanna Strand, Sven-Erik Strand, Bo Åkerström and Anders Örbom
Pharmaceutics 2022, 14(4), 731; https://doi.org/10.3390/pharmaceutics14040731 - 28 Mar 2022
Cited by 5 | Viewed by 2734
Abstract
Prostate cancer (PC) is one of the most common malignancies affecting men, with poor prognosis after progression to metastatic castration-resistant prostate cancer (mCRPC). Radioligand therapy (RLT) targeting the overexpressed PSMA on PC cells, with, e.g., 177Lu-PSMA-617, has been effective in reducing tumor [...] Read more.
Prostate cancer (PC) is one of the most common malignancies affecting men, with poor prognosis after progression to metastatic castration-resistant prostate cancer (mCRPC). Radioligand therapy (RLT) targeting the overexpressed PSMA on PC cells, with, e.g., 177Lu-PSMA-617, has been effective in reducing tumor burden and prolonging survival in mCRPC. However, it is not a curative method with kidney and bone marrow toxicity limiting the activity given to patients. Previous preclinical models have reported transient hematotoxicity for up to 120 MBq. This activity may still be too low to investigate the effect on renal function since it corresponds to an absorbed dose below 10 Gy, whereas the kidneys in a clinical setting usually receive an absorbed dose more than double. Here we investigated the hematotoxicity and recovery after administered activities of 120, 160, and 200 MBq in a 177Lu-PSMA-617 BALB/cAnNRj mouse model. The animals had an initial drop in white blood cells (WBC) starting 4 days post injection, which recovered after 21 days. The effect on red blood cells (RBC) and platelets was detected later; 17 days post-injection levels decreased compared to the control group. The reduction was restored again 32 days post injection. No correlation between injected activity and hematotoxicity was found. Our results suggest that activities up to 200 MBq of 177Lu-PSMA-617 give transient hematotoxicity from which animals recover within a month and no radiation-related deaths. Injecting these high activities could allow animal studies with increased clinical relevance when studying renal toxicity in animal models. Full article
(This article belongs to the Special Issue Radionuclide-Based Theranostics)
►▼ Show Figures

Figure 1

Review

Jump to: Research

13 pages, 706 KiB  
Review
Integrin-αvβ3 as a Therapeutic Target in Glioblastoma: Back to the Future?
by William Echavidre, Vincent Picco, Marc Faraggi and Christopher Montemagno
Pharmaceutics 2022, 14(5), 1053; https://doi.org/10.3390/pharmaceutics14051053 - 13 May 2022
Cited by 23 | Viewed by 5892
Abstract
Glioblastoma (GBM), the most common primary malignant brain tumor, is associated with a dismal prognosis. Standard therapies including maximal surgical resection, radiotherapy, and temozolomide chemotherapy remain poorly efficient. Improving GBM treatment modalities is, therefore, a paramount challenge for researchers and clinicians. GBMs exhibit [...] Read more.
Glioblastoma (GBM), the most common primary malignant brain tumor, is associated with a dismal prognosis. Standard therapies including maximal surgical resection, radiotherapy, and temozolomide chemotherapy remain poorly efficient. Improving GBM treatment modalities is, therefore, a paramount challenge for researchers and clinicians. GBMs exhibit the hallmark feature of aggressive invasion into the surrounding tissue. Among cell surface receptors involved in this process, members of the integrin family are known to be key actors of GBM invasion. Upregulation of integrins was reported in both tumor and stromal cells, making them a suitable target for innovative therapies targeting integrins in GBM patients, as their impairment disrupts tumor cell proliferation and invasive capacities. Among them, integrin-αvβ3 expression correlates with high-grade GBM. Driven by a plethora of preclinical biological studies, antagonists of αvβ3 rapidly became attractive therapeutic candidates to impair GBM tumorigenesis. In this perspective, the advent of nuclear medicine is currently one of the greatest components of the theranostic concept in both preclinical and clinical research fields. In this review, we provided an overview of αvβ3 expression in GBM to emphasize the therapeutic agents developed. Advanced current and future developments in the theranostic field targeting αvβ3 are finally discussed. Full article
(This article belongs to the Special Issue Radionuclide-Based Theranostics)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop